Abridge vs DeepScribe (2026)
Both sides of this pairing hold A grades on evidence and EHR depth, so the split is scope against specialty. Abridge is the enterprise reference standard: Best in KLAS for Ambient AI in 2025 and 2026, the largest independent peer reviewed study in the category with 1,306 clinicians at Kaiser Permanente published in NEJM AI, native Epic depth across Haiku, Canto, and Hyperdrive, and coverage spanning more than 55 specialties across outpatient, inpatient, and emergency settings. DeepScribe went deep instead of wide: oncology is its center of gravity with a reported 40 percent of US cancer care visits, tuned models for six further specialties, and the highest independent rating in the lane at 98.8 on the KLAS Emerging Company Spotlight. If your failure mode is a system wide rollout across settings that compliance must be able to audit, start with Abridge. If your failure mode is complex specialty documentation that generalist scribes get wrong, oncology above all, start with DeepScribe. Neither publishes pricing.
- The evidence bar decides it: the largest independent peer reviewed study in the category, 1,306 clinicians at Kaiser Permanente published in NEJM AI, corroborated by Best in KLAS for Ambient AI in both 2025 and 2026, which is buyer survey based rather than vendor asserted.
- Compliance needs an audit trail: Linked Evidence maps every part of a generated note back to the source audio so a clinician can verify any sentence against what was said before signing, a control DeepScribe does not document.
- Setting breadth is the requirement: more than 28 languages and 55 specialties across outpatient, inpatient, and emergency settings, with native Epic embedding extending into structured orders and real time prior authorization.
- Specialty depth is the requirement: oncology first with a reported 5 million oncology visits a year and roughly 40 percent of US cancer care visits documented, plus tuned models for cardiology, urology, gastroenterology, orthopedics, neurology, and nephrology.
- The independent rating is the strongest in the lane: a 98.8 KLAS Emerging Company Spotlight score with A plus marks across all six measured categories, plus 2025 KLAS Top 5 rankings and an August 2025 Journal of Clinical Pathways study in oncology.
- Longitudinal chart awareness: reads problems, medications, labs, and prior notes before the encounter and writes structured data into discrete EHR fields after, with HCC, CPT, and ICD-10 suggestions built into the note.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Abridge and DeepScribe are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Abridge | DeepScribe |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2018 | 2017 |
| Headquarters | Pittsburgh, Pennsylvania | San Francisco, California |
| Website | abridge.com | deepscribe.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Abridge its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model Supply Chain Disclosure. Set against DeepScribe, Abridge grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards DeepScribe its top capability grade on several axes, including AI Centrality, Clinical and Operational Evidence and EHR and Interoperability Depth. Set against Abridge, DeepScribe does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Clinical and Operational Evidence and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Abridge or DeepScribe?
The AI Health Index grades Abridge higher than DeepScribe on every axis that separates them, several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. DeepScribe does not grade higher on any scored axis.
Where do Abridge and DeepScribe differ most?
The widest separation the AI Health Index records between Abridge and DeepScribe is on Model Supply Chain Disclosure, where Abridge grades A and DeepScribe grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Abridge and DeepScribe grade the same?
The AI Health Index grades Abridge and DeepScribe the same on several axes, including AI Centrality, Clinical and Operational Evidence and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Deployment counts and market share figures for both vendors are vendor published, including Abridge's 250 plus health systems and DeepScribe's oncology share. Both evidence grades reflect the scale, venue, and independence of the cited studies and ratings rather than a re verification of their findings, and the KLAS instruments differ: Best in KLAS category awards for Abridge against the Emerging Company Spotlight for DeepScribe. Neither vendor publishes pricing.
Third party estimates recorded in this index place Abridge near $2,500 per clinician per year and DeepScribe at $350 to $500 per provider per month, with some reports near $750; all are unconfirmed estimates.